Evaluation of Human Hepatocyte Drug Metabolism Carrying High-Risk or Protection-Associated Liver Disease Genetic Variants

Evaluation of Human Hepatocyte Drug Metabolism Carrying High-Risk or Protection-Associated Liver Disease Genetic Variants

Metabolic-dysfunction-associated steatotic liver disease (MASLD), which affects 30 million people in the US and is anticipated to reach over 100 million by 2030, places a significant financial strain on the healthcare system. There is presently no FDA-approved treatment for MASLD despite its public...

Full description

Bibliographic Details
Main Authors: Lanuza A. P. Faccioli, Zeliha Cetin, Zehra N. Kocas-Kilicarslan, Kimberly Ortiz, Yiyue Sun, Zhiping Hu, Takeshi Kurihara, Edgar N. Tafaleng, Rodrigo M. Florentino, Zi Wang, Mengying Xia, Mark T. Miedel, D. Lansing Taylor, Jaideep Behari, Alina Ostrowska, Robert Constantine, Albert Li, Alejandro Soto-Gutierrez
Format: Article
Language:English
Published: MDPI AG 2023-08-01
Series:International Journal of Molecular Sciences
Subjects:
metabolic-dysfunction-associated steatotic liver disease
metabolic dysfunction-associated steatohepatitis
nonalcoholic steatohepatitis
end-stage liver disease
genetic polymorphisms
Online Access:https://www.mdpi.com/1422-0067/24/17/13406

Internet

https://www.mdpi.com/1422-0067/24/17/13406

Similar Items